276 related articles for article (PubMed ID: 32348197)
21. The relationship between opioid agonist therapy satisfaction and fentanyl exposure in a Canadian setting.
Mackay L; Kerr T; Fairbairn N; Grant C; Milloy MJ; Hayashi K
Addict Sci Clin Pract; 2021 Apr; 16(1):26. PubMed ID: 33910630
[TBL] [Abstract][Full Text] [Related]
22. Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
Bozinoff N; DeBeck K; Milloy MJ; Nosova E; Fairbairn N; Wood E; Hayashi K
Drug Alcohol Depend; 2018 Dec; 193():42-47. PubMed ID: 30340144
[TBL] [Abstract][Full Text] [Related]
23. Patterns of substance use and mortality risk in a cohort of 'hard-to-reach' polysubstance users.
Gjersing L; Bretteville-Jensen AL
Addiction; 2018 Apr; 113(4):729-739. PubMed ID: 28987019
[TBL] [Abstract][Full Text] [Related]
24. Risk of non-fatal overdose and polysubstance use in a longitudinal study with people who inject drugs in Tijuana, Mexico.
Rivera Saldana CD; Abramovitz D; Meacham MC; Gonzalez-Zuniga P; Rafful C; Rangel G; Strathdee SA; Cepeda J
Drug Alcohol Rev; 2021 Nov; 40(7):1340-1348. PubMed ID: 34042226
[TBL] [Abstract][Full Text] [Related]
25. Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery.
Nielsen T; Bernson D; Terplan M; Wakeman SE; Yule AM; Mehta PK; Bharel M; Diop H; Taveras EM; Wilens TE; Schiff DM
Addiction; 2020 Feb; 115(2):291-301. PubMed ID: 31692133
[TBL] [Abstract][Full Text] [Related]
26. Crystal methamphetamine use subgroups and associated addiction care access and overdose risk in a Canadian urban setting.
Brooks O; Bach P; Dong H; Milloy MJ; Fairbairn N; Kerr T; Hayashi K
Drug Alcohol Depend; 2022 Mar; 232():109274. PubMed ID: 35033951
[TBL] [Abstract][Full Text] [Related]
27. Effect of witnessing an overdose on the use of drug checking services among people who use illicit drugs in Vancouver, Canada.
Beaulieu T; Hayashi K; Nosova E; Milloy MJ; DeBeck K; Wood E; Kerr T; Ti L
Am J Drug Alcohol Abuse; 2020 Jul; 46(4):506-511. PubMed ID: 31983241
[TBL] [Abstract][Full Text] [Related]
28. Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.
Socías ME; Dong H; Wood E; Nolan S; Hayashi K; Kerr T; Milloy MJ
Am J Prev Med; 2021 Jan; 60(1):57-63. PubMed ID: 33341181
[TBL] [Abstract][Full Text] [Related]
29. Investigating opioid preference to inform safe supply services: A cross sectional study.
Ferguson M; Parmar A; Papamihali K; Weng A; Lock K; Buxton JA
Int J Drug Policy; 2022 Mar; 101():103574. PubMed ID: 35007878
[TBL] [Abstract][Full Text] [Related]
30. Prescription opioid use and non-fatal overdose in a cohort of injection drug users.
Lake S; Wood E; Buxton J; Dong H; Montaner J; Kerr T
Am J Drug Alcohol Abuse; 2015 May; 41(3):257-63. PubMed ID: 25699628
[TBL] [Abstract][Full Text] [Related]
31. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Pearce LA; Min JE; Piske M; Zhou H; Homayra F; Slaunwhite A; Irvine M; McGowan G; Nosyk B
BMJ; 2020 Mar; 368():m772. PubMed ID: 32234712
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and correlates of multiple non-fatal opioid overdoses among people who inject drugs who utilise needle syringe programs in Australia.
Geddes L; Iversen J; Darke S; Dietze P; Maher L
Int J Drug Policy; 2021 Oct; 96():103245. PubMed ID: 33840562
[TBL] [Abstract][Full Text] [Related]
33. High prevalence of non-fatal overdose among people who inject drugs in Malaysia: Correlates of overdose and implications for overdose prevention from a cross-sectional study.
Bazazi AR; Zelenev A; Fu JJ; Yee I; Kamarulzaman A; Altice FL
Int J Drug Policy; 2015 Jul; 26(7):675-81. PubMed ID: 25532449
[TBL] [Abstract][Full Text] [Related]
34. Polysubstance use latent class membership in New Jersey: Association with prior overdoses, prior emergency department peer recovery engagement, and mental health diagnosis among participants in an opioid overdose recovery program.
Lardier DT; Gilmore Powell K; Peterson NA; Borys S; Hallcom DK
Subst Abus; 2022; 43(1):1011-1022. PubMed ID: 35435801
[No Abstract] [Full Text] [Related]
35. Associations with experience of non-fatal opioid overdose in British Columbia, Canada: a repeated cross sectional survey study.
Ferguson M; Choisil P; Lamb J; Burmeister C; Newman C; Lock K; Tobias S; Liu L; Buxton JA
Harm Reduct J; 2023 Dec; 20(1):178. PubMed ID: 38093272
[TBL] [Abstract][Full Text] [Related]
36. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia.
Kamal A; Ferguson M; Xavier JC; Liu L; Graham B; Lock K; Buxton JA
Subst Abuse Treat Prev Policy; 2023 May; 18(1):27. PubMed ID: 37194018
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and longitudinal correlates of recent exposure to fentanyl among HIV-positive people who use unregulated drugs during a community-wide overdose crisis.
Moallef S; Nosova E; Nolan S; Fairbairn N; Loh J; Hayashi K; Milloy MJ
AIDS Care; 2021 Dec; 33(12):1560-1568. PubMed ID: 33764814
[TBL] [Abstract][Full Text] [Related]
38. Known fentanyl use among clients of harm reduction sites in British Columbia, Canada.
Karamouzian M; Papamihali K; Graham B; Crabtree A; Mill C; Kuo M; Young S; Buxton JA
Int J Drug Policy; 2020 Mar; 77():102665. PubMed ID: 31962283
[TBL] [Abstract][Full Text] [Related]
39. Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis.
Socías ME; Choi J; Lake S; Wood E; Valleriani J; Hayashi K; Kerr T; Milloy MJ
Drug Alcohol Depend; 2021 Feb; 219():108420. PubMed ID: 33342591
[TBL] [Abstract][Full Text] [Related]
40. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
